Cytomegalovirus Antibody Screening Test

Overview :

When first exposed to CMV, a person's immune system is triggered and quickly makes antibodies to fight the virus. Antibodies are special proteins designed to attack and destroy foreign material, in this case, the cytomegalovirus.

The test combines a person's serum with a substance to which CMV antibodies attach. This antibody-antigen complex is measured and the amount of original antibody determined. If positive for antibodies, the serum is diluted, or titered, and the test repeated until the serum is so dilute it no longer gives a positive result. The last dilution that gives a positive result is the titer reported.

A test positive for CMV antibodies means the person has been infected with the virus, either currently or in the past; it does not mean the person has lifetime immunity. After an infection, this virus, like all members of the herpes virus group, can stay hidden inside a person and cause infection if the person's immune system later weakens and antibody protection decreases. In fact, reactivation of such hidden (or latent) infection is not at all uncommon and usually occurs without symptoms.

Transplant patients and people with weakened immune systems, including those with HIV, are vulnerable to infection from several routes, including from another person, from a donated organ or transfused blood, or from reactivation of a past infection. Before transplant, both the recipient and donor are usually tested for antibodies. A recipient who has never had CMV (negative for antibodies), should not receive an organ from a donor who has had CMV (positive for antibodies). CVM infection can be associated with organ rejection, or can cause illness such as pneumonia, hepatitis, or death. Similarly, blood is usually screened for CMV antibodies before being transfused into a person with a weakened immune system.

CMV infection is the most common congenital infection (existing at birth). The infection, passed from mother to baby, can cause permanent mental or physical damage, or death. The antibody screening test tells a woman whether or not she has antibody protection against the virus in case she is exposed during pregnancy. Pregnant women 25 years and older who are immune to CMV are much less likely to pass the virus to their babies than younger women who have never been exposed to CMV.

Tests that measure a specific type of antibody help tell the difference between a current and a past infection. Immunoglobulin M (IgM) antibodies appear at the beginning of an infection and last only weeks. Immunoglobulin G (IgG) antibodies appear 10-14 days later and can last a lifetime. A person suspected of having a current infection should be tested at the beginning of the infection and again 10-14 days later.

The CMV antibody screening test is also called the transplant reaction screening test. Results are usually available the following day.

It may be possible to test fetal blood for certain antibodies to CMV virus by drawing a blood sample from the umbilical cord. This may be an important test to add to prenatal care, since newborn babies with CMV often show no symptoms.